vimarsana.com

Discussion Session Date News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Triumvira Immunologics Highlights Positive Phase 1 Clinical Data on TAC01-HER2 in Solid Tumors at ASCO 2023 Annual Meeting

Antengene To Present Latest Results from TORCH-2 Study of ATG-008 in Advanced Solid Tumors in Poster Discussion at ASCO 2023

Tvardi Therapeutics Announces Presentation of Data from the Phase 1 Trial of TTI-101, a STAT3 inhibitor, in Advanced Solid Tumors at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.